Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1358 • ACR Convergence 2025
Real-World Evidence for the Superiority of Subcutaneous Methotrexate in RA: A Comparative Observational Study with Ultrasonographic Assessment
Masatsugu Komagamine¹, Sari Taguchi², Masataka Komagamine², Tetsuji Naka¹ and Minoru Fujimoto¹, ¹Division of Allergy and Rheumatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan, ²Komagamine Rheumatology and Orthopedic Clinic, Morioka, Japan
Background/Purpose: Methotrexate (MTX) is a foundational agent in the management of rheumatoid arthritis (RA). While oral MTX is widely prescribed, its subcutaneous (SC) formulation may…
Abstract Number: 1341 • ACR Convergence 2025
Physical Function Across Age in Patients With Rheumatoid Arthritis and Population Controls: A Cross-Sectional Study of Four Performance Measures
Saskia Truijen¹, Annelies Boonen¹, Sofia Ramiro² and Marloes van Onna¹, ¹Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands, ²Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) may accelerate age-related functional decline compared to the general population. This study aimed to examine whether four performance measures of physical…
Abstract Number: 1324 • ACR Convergence 2025
Similar Negative Effects of Fatigue on Physical Activity in Persons with Rheumatoid Arthritis and Healthy Controls: A Patient-Control Study
Maartje Cox¹, Kyra Theunissen², Kenneth Meijer², Annick Timmermans³, Sofia Ramiro⁴, Annelies Boonen⁵ and Guy Plasqui², ¹Australian National Phenome Centre - Murdoch University, Booragoon, Western Australia, Australia, ²Maastricht University, Maastricht, Netherlands, ³Universiteit Hasselt, Hasselt, ⁴Leiden University Medical Center, Bunde, Netherlands, ⁵Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands
Background/Purpose: People with rheumatoid arthritis (pwRA) are prone to fall short of the World Health Organization’s physical activity (PA) recommendations due to perceived fatigue and…
Abstract Number: 1308 • ACR Convergence 2025
Predictors of Interstitial Lung Disease Progression in Patients with Rheumatoid Arthritis
Bryant England¹, Austin Wheeler¹, Halie Frideres², Scott Matson³, Geoffrey Thiele¹, Katherine Wysham⁴, Grant Cannon⁵, Gary Kunkel⁶, Gail Kerr⁷, Andreas Reimold⁸, John Richards⁹, Dana Ascherman¹⁰, Paul Monach¹¹, Joshua Baker¹² and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC Department of Rheumatology, Omaha, NE, ³University of Kansas, Kansas City, MO, ⁴VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁷Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁸Dallas VA Medical Center, Dallas, TX, ⁹Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹⁰University of Pittsburgh, Pittsburgh, PA, ¹¹VA Boston Healthcare System, Boston, MA, ¹²University of Pennsylvania, Philadelphia, PA
Background/Purpose: Interstitial lung disease (ILD) is a frequent extra-articular manifestation of RA predisposing to poor health outcomes. The disease course in RA-ILD is variable, with…
Abstract Number: 1110 • ACR Convergence 2025
Tumor outcomes and arthritis flares in patients with pre-existing rheumatoid arthritis receiving immune checkpoint inhibitor therapy
Madalyn Walsh¹, Jeremy Zhang², Bashar Abuqayas¹, Sanchay Jain³, Yosef Zakharia⁴, Aleksander Lenert⁵ and Jennifer Strouse⁶, ¹University of Iowa Hospitals & Clinics, Iowa City, IA, ²Rush University, Chicago, IL, ³University of Iowa, Iowa City, IA, ⁴Mayo Clinic, Rochester, MN, ⁵Iowa Carver College of Medicine, Iowa City, IA, ⁶University of Iowa, Iowa City
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of an increasing number of malignancies. Because patients with pre-existing autoimmune disease have been excluded from…
Abstract Number: 1033 • ACR Convergence 2025
Rethinking ANA in Rheumatoid Arthritis: ICAP Pattern Insights from a Large-Scale Taiwanese Cohort
Tien-Ming Chan, Chang Gung Memorial Hospital, Taoyuan, Taiwan (Republic of China)
Background/Purpose: ANA prevalence and patterns vary in RA. Using ICAP nomenclature, this study aimed to determine the prevalence of RA across different ANA patterns and…
Abstract Number: 0930 • ACR Convergence 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Blocks Pro-Inflammatory Cytokines and Reduces Joint Swelling in a Mouse Model of Rheumatoid Arthritis
Ryan Camire¹, Yi Zhang², Virginia Massa², Jordan Leedberg², Erik Corcoran², Emily Lurier², Chris Carroll², Chris Ho², Dapeng Chen², Bradley Enerson², Revonda Mehovic², Ziyan Zhao², Lincoln Howarth², Susanne Breitkopf², Sarah Martinez², Melissa Ford², Xue Fei², Murugappan Sathappa², Juliet Williams³, Matthew Weiss³, Arsalan Shabbir³, Nello Mainolfi⁴ and Veronica Campbell², ¹Kymera Therapeutics, Watertown, MA ⁰²⁴⁷², MA, ²Kymera Therapeutics, Watertown, MA ⁰²⁴⁷², ³Kymera Therapeutics, Watertown, ⁴Kymera Therapeutics, Watertown, MA
Background/Purpose: IRF5, an undrugged transcription factor, is an autoimmune susceptibility gene that has been linked to RA and other autoimmune diseases including SLE, Sjögren’s, and…
Abstract Number: 0850 • ACR Convergence 2025
Single-cell RNA-seq analysis of synovial CD4+ T cells identifies a novel biomarker and therapeutic target in human rheumatoid arthritis
Akinori Murakami¹, Rinko Akamine¹, Koichi Murata¹, Kohei Nishitani¹, Hiromu Ito², Ryu Watanabe³, Takayuki Fujii¹, Takeshi Iwasaki¹, Yuki Masuo⁴, Osamu Iri¹, Shinichiro Nakamura¹, Shinichi Kuriyama¹, Yugo Morita¹, Yasuhiro Murakawa⁵, Chikashi Terao⁶, Yukinori Okada⁷, Motomu Hashimoto³, Shuichi Matsuda¹, Hideki Ueno¹ and Hiroyuki Yoshitomi¹, ¹Kyoto University, Kyoto, Japan, ²Kyoto University / Kurashiki Central Hospital, Kyoto, Japan, ³Osaka Metropolitan University, Osaka, Japan, ⁴Graduate school of medicine, Kyoto University, Kyoto, Japan, ⁵Kyoto University / RIKEN, Kyoto, Japan, ⁶RIKEN, Tokyo, Japan, ⁷The University of Tokyo / Osaka University / RIKEN, Tokyo, Japan
Background/Purpose: CD4+ T cells play a central role in the pathogenesis of human rheumatoid arthritis (RA). However, therapies targeting CD4+ T cell-derived humoral factors, including…
Abstract Number: 0796 • ACR Convergence 2025
Deciphering Synovial Fluid Immune Dysregulation in Rheumatoid Arthritis through Cytokine Profiling and Single-Cell Transcriptomics
Manon LESTURGIE-TALAREK¹, Francesco Carbone², Virginie Gonzalez³, Adrien Schvartz², Sophie Hecquet⁴, Fiona Oudart⁵, Marion Thomas⁶, Roberto D'Alessandro⁷, Yannick Allanore⁸, Mickael Menager² and Jérôme AVOUAC⁹, ¹Paris University, Paris, France, ²Institut Imagine, Paris, ³INSERMU¹⁰¹⁶, Paris, France, ⁴Cochin Hospital, Paris, France, ⁵APHP - Cochin hospital, Paris, France, ⁶APHP, Paris, France, ⁷Cochin Hospital, Paris, ⁸Université Paris Cité, Paris, France, ⁹Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) is driven by complex inflammatory pathways involving immune cell infiltration into synovial tissue and fluid. Synovial fluid (SF) provides direct insight…
Abstract Number: 0493 • ACR Convergence 2025
Phase I Trial in Participants with Rheumatoid Arthritis and Healthy Volunteers with CIT-013, a First in Class NETosis Inhibitor
Maarten Kraan¹, Salah Hadi², Leonie Middelink³, Renato Chirivi³, Eric meldrum³, Naomi Klarenbeek⁴ and Patrick Round³, ¹Citryll BV, Den Dolder, Netherlands, ²ICON Netherlands BV, Groningen, Netherlands, ³Citryll BV, Oss, Netherlands, ⁴CHDR, Leiden, Netherlands
Background/Purpose: Aberrant Neutrophil Extracellular Trap (NET) production contributes to the pathophysiology of multiple inflammatory and autoimmune diseases including rheumatoid arthritis (RA). We report data of…
Abstract Number: 0477 • ACR Convergence 2025
At the patient level, ultrasound evaluation during the follow up of rheumatoid arthritis does not modify radiographic evolution: a prospective, multicenter, randomized, pragmatic clinical trial (BCD study)
Alexandre GARMENDIA¹, Valerie Devauchelle², Grégoire CORMIER³, LE GOFF Benoit⁴, Aleth Perdriger⁵, Saloua Mammou⁶, Emannuel Hoppe⁷, Emmanuelle Dernis⁸, Jose Le Noach⁹, Carine Salliot¹⁰, florent garrigues¹, Raphael Auffret¹, Ichem Mohtarif¹¹, Mateusz Chodorowsky¹¹, Thierry MARHADOUR¹², Divi Cornec¹³, Dewi Guellec¹, Emmanuelle Courtois Communier¹, Alain SARAUX¹⁴ and sandrine jousse¹², ¹CHU de BREST, Brest, Bretagne, France, ²UBO, Brest, France, ³Centre Hospitalier département de Vendée, La Roche Sur Yon, France, ⁴CHU Nantes, Nantes, France, ⁵Rennes University, Rennes, France, ⁶CHU TOURS, TOURS, France, ⁷CHU ANGERS, Angers, France, ⁸Rheumatology Department, Le Mans Central Hospital, Le Mans, France, LE MANS, France, ⁹Centre Hospitalier de Lorient, Lorient, France, ¹⁰CHR orleans, Orleans, France, ¹¹CHU de Brest, Brest, France, ¹²LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ¹³Departement of Rhumatology, CHU Brest, Université de Brest, INSERM UMR¹²²⁷: LBAI, Brest, France, Brest, France, ¹⁴CHU Brest, Brest, France
Background/Purpose: Previous studies, including TASER and ARTIC (1,2), failed to demonstrate a significant benefit of ultrasound (US) compared to clinical evaluation in achieving clinical remission…
Abstract Number: 0461 • ACR Convergence 2025
Right Diagnoses For the Wrong Reasons: Limitations of Current Large-Language Model based Agentic Frameworks for Screening of Rheumatoid Arthritis
Sarthak Verma¹, Avarna Agarwal¹, Umakanta Maharana², Murari Mandal³, Prasanta Padhan¹, Prakashini Mruthyanjaya⁴ and Sakir Ahmed¹, ¹Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, Orissa, India, ²School of Computer Engineering, KIIT University, Bhubaneswar, India, ³School of Computer Engineering, KIIT University, Bhubaneswar, Orissa, India, ⁴Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, India
Background/Purpose: In India, Rheumatoid arthritis (RA) is often diagnosed late. Artificial Intelligence (AI) driven Large Language models (LLMs) can be deployed via widely available mobile…
Abstract Number: 0444 • ACR Convergence 2025
Low Disease Activity: Good Enough?
Emily Thoman¹, Sebastiano Porcu¹ and Martin Bergman², ¹Lankenau Medical Center, Wynnewood, PA, ²Drexel University College of Medicine, Philadelphia
Background/Purpose: Treat-to-target is the guiding principle and therapeutic strategy for rheumatoid arthritis (RA) treatment. Escalation of treatment is based on the regular assessment of disease…
Abstract Number: 0378 • ACR Convergence 2025
Identifying Patterns of Telemedicine Readiness and Digital Health Literacy in Rheumatoid Arthritis Patients: A Latent Class Analysis
Preeti Dhanasekaran¹, Bryant Lim², Qai Ven Yap², Hafizah Ahmad³, Siew Hwa Chong³, Ginny Goh³, Manjari Lahiri⁴, Amelia Santosa⁴, Gim Gee Teng³, Peter Cheung⁴, Siriwan Lim¹ and Margaret Ma⁴, ¹National University of Singapore, Singapore, Singapore, ²National University of Singapore, Singapore, ³National University Hospital, Singapore, ⁴National University Hospital, Singapore, Singapore
Background/Purpose: The COVID-19 pandemic accelerated telemedicine adoption, yet readiness and digital literacy vary widely across patient populations. Understanding these differences is crucial to designing equitable…
Abstract Number: 0214 • ACR Convergence 2025
Systematic Comorbidity Screening in Inflammatory Arthritis: The Experience of a Tertiary-Care Centre
Camille Bourgeois¹, Alexandra Kobza², Olivier Fogel³, Maxime Dougados⁴ and Anna Molto⁵, ¹Hospital general universitario Gregorio Marañon, Madrid, Madrid, Spain, ²University of Calgary, North Vancouver, BC, Canada, ³AP-HP, Paris, France, ⁴Department of Medicine, Hopital Cochin, Universite de Paris, Paris, France, ⁵Assistance Publique Hôpitauxde Paris, Paris, France
Background/Purpose: Patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA) and spondyloarthritis (SpA), are at elevated risk for comorbidities, complicating disease management. Despite rheumatology societies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].